42nd Annual J.P. Morgan Healthcare Conference Transcript

Host: Hope you’re have hope you had a great day for at the J. P. Morgan Healthcare Conference. I’m Bhavna Balakrishnan, an associate here in the Healthcare Investment Banking Team. Thank you so much for joining the presentation of Xeris Biopharma. With us today, we have Paul Edick, who is the Chairman and Chief Executive…

Xeris Pharma: A Rising Star in the Pharmaceutical Landscape (XERS)

In a recent enlightening interview at the H. C. Wainwright’s 25th Annual Global Investment Conference, Xeris Pharma’s promising trajectory was laid bare for all to see. With CEO Paul Edick and CFO Steve Pieper at the helm, the company’s future has never looked brighter. Here’s why every investor should be bullish about Xeris Pharma. 1….

Insights from ChatGPT: Xeris Biopharma Q1 2023 Earnings Call

What does ChatGPT think about Xeris’ Q1 2023 earnings call. The following is the conversation we had: Summarizing Q1 2023 Earnings Call Transcript I’m going to post an earnings call in a few different sections. Do not summarize until all sections are posted and I will let you know they are all posted by the…

Gvoke Sales Surge and Close Gap on Baqsimi in Diabetes Treatment Market

An article written by ChatGPT In the world of diabetes treatment, patients have a range of options for emergency hypoglycemic events. Two of the leading products on the market are Gvoke and Baqsimi, both of which provide a rapid-response method of treating low blood sugar. However, recent data suggests that Gvoke sales have been gaining…

J.P. Morgan Healthcare Conference 2023 Transcript

Transcription may have some errors – apologize in advance Paul Edick – I would remind everyone to pay attention to our forward looking statements. Investing is always a risk. We’ll start out with an overview of the company. Xeris has a very diversified revenue base. We have three marketed assets, all growing record level. I’ll…

Q1 2022 Earning Call Audio & Transcription

Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Updated with Seeking Alpha transcript: Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30…

Q4 2021 Earning Call Audio & Transcription

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey – SVP, IR and Corporate Communications Paul Edick – Chairman and CEO Steve Pieper – CFO Conference Call Participants Roanna Ruiz – SVB Leerink Vamil Divan – Mizuho Securities David Amsellem – Piper Sandler Operator Hello everyone….

Fireside Chat with Paul Edick – Xeris Biopharma – $XERS

Fireside chat with Paul Edick – CEO of Xeris Biopharma – $XERS

What Lies Ahead For Xeris Biopharma In 2022

Jan. 1 PDUFA for Recorlev, Merck collaboration, Levothyroxine Phase 1, EIH Phase 2, and growing sales for Gvoke and Keveyis; Xeris has great potential for 2022.

2021 Q3 Earnings Call Recording

Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Edit: Transcription has been updated using Seeking Alpha | Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2021 Earnings Conference Call November 10,…